Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HS-10504 vs Platinum-Based Doublet Chemotherapy in Advanced NSCLC with EGFR C797S Mutation
NCT07754123Phase 3Recruiting
- Sponsor
- Hansoh Pharmaceutical Group
- Start
- Oct 2026
- Primary completion
- Aug 2028
- Countries
- 1
01
Overview
A Phase 3 trial of HS-10504 in non-small cell lung cancer (NSCLC), sponsored by Hansoh Pharmaceutical Group. Started Oct 2026; status: recruiting.
02
Drugs
HS-10504
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07754123.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07754123.